|Hospital:||University Hospital Rotterdam|
|Patients: This Phase II trial involved 32 patients with malignant pleural mesothelioma. None of these patients had received prior chemotherapy.|
Treatment: The treatment consisted of two chemotherapy drugs, gemcitabine (gemzar) and cisplatin (platinol).
Toxicity: Grade 4 toxicities included nausea and vomiting. Grade 3 toxicities included hematologic, nausea and vomiting, fatigue anorexia, diarrhea, neurotoxicity, cardiovascular.
Results: The median survival from the start of treatment was 9.4 months.
Support: This study was supported in part by Lilly BV. Lilly markets gemzar.
Correspondence: JP van Meerbeeck, MD